JUHE:XETRA:XETRA-JPMorgan ETFs (Ireland) ICAV - US Research Enhanced Index Equity UCITS ETF - EUR Hedged (acc) (EUR)

ETF | Others |

Last Closing

USD 42.87

Change

0.00 (0.00)%

Market Cap

N/A

Volume

294.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-11 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.09 (-0.18%)

USD 473.61B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.21%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.08 (-0.30%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.15 (-0.52%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.76 (-0.47%)

USD 126.93B
JARI:XETRA Amundi Index Solutions - Amund..

+0.15 (+0.33%)

USD 105.55B
8R80:XETRA Amundi Index Solutions - Amund..

-0.66 (-0.46%)

USD 99.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.12 (-0.24%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.72 (-0.14%)

USD 80.38B

ETFs Containing JUHE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.95% 69% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.95% 69% C- 68% D+
Trailing 12 Months  
Capital Gain 27.70% 84% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.70% 84% B 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.55% 67% D+ 64% D
Dividend Return 7.55% 65% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.72% 56% F 64% D
Risk Adjusted Return 64.39% 80% B- 81% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike